Next Article in Journal
“Balancing Expectations with Actual Realities”: Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial
Previous Article in Journal
Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program
Open AccessReview

Harnessing the Potential of Stem Cells for Disease Modeling: Progress and Promises

1
Department of Chemistry, Biology and Biotechnologies, University of Perugia, Via del Giochetto, 06126 Perugia, Italy
2
CEMIN, Center of Excellence on Nanostructured Innovative Materials, Via del Giochetto, 06126 Perugia, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
J. Pers. Med. 2020, 10(1), 8; https://doi.org/10.3390/jpm10010008
Received: 12 December 2019 / Revised: 18 January 2020 / Accepted: 1 February 2020 / Published: 6 February 2020
Ex vivo cell/tissue-based models are an essential step in the workflow of pathophysiology studies, assay development, disease modeling, drug discovery, and development of personalized therapeutic strategies. For these purposes, both scientific and pharmaceutical research have adopted ex vivo stem cell models because of their better predictive power. As matter of a fact, the advancing in isolation and in vitro expansion protocols for culturing autologous human stem cells, and the standardization of methods for generating patient-derived induced pluripotent stem cells has made feasible to generate and investigate human cellular disease models with even greater speed and efficiency. Furthermore, the potential of stem cells on generating more complex systems, such as scaffold-cell models, organoids, or organ-on-a-chip, allowed to overcome the limitations of the two-dimensional culture systems as well as to better mimic tissues structures and functions. Finally, the advent of genome-editing/gene therapy technologies had a great impact on the generation of more proficient stem cell-disease models and on establishing an effective therapeutic treatment. In this review, we discuss important breakthroughs of stem cell-based models highlighting current directions, advantages, and limitations and point out the need to combine experimental biology with computational tools able to describe complex biological systems and deliver results or predictions in the context of personalized medicine. View Full-Text
Keywords: organoids; organ-on-a-chip; iPSCs; gene therapy; genome editing; tissue engineering; computational cell modeling organoids; organ-on-a-chip; iPSCs; gene therapy; genome editing; tissue engineering; computational cell modeling
Show Figures

Figure 1

MDPI and ACS Style

Argentati, C.; Tortorella, I.; Bazzucchi, M.; Morena, F.; Martino, S. Harnessing the Potential of Stem Cells for Disease Modeling: Progress and Promises. J. Pers. Med. 2020, 10, 8.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop